Equities

Hikma Pharmaceuticals PLC

HIK:LSE

Hikma Pharmaceuticals PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,540.00
  • Today's Change-12.00 / -0.77%
  • Shares traded1.15m
  • 1 Year change-32.87%
  • Beta1.1634
Data delayed at least 20 minutes, as of Feb 06 2026 14:55 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.

  • Revenue in GBP (TTM)2.40bn
  • Net income in GBP274.31m
  • Incorporated2005
  • Employees9.31k
  • Location
    Hikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
  • Phone+44 20 7399 2760Fax+44 20 7399 2761
  • Websitehttps://www.hikma.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Laboratorios Farmaceuticos ROVI SA630.44m105.47m3.26bn2.19k3.26bn2.19k
TG Therapeutics Inc393.17m330.76m3.26bn374.003.26bn374.00
Xuanzhu Biopharmaceutical Co Ltd3.40m-59.23m3.26bn197.003.26bn197.00
Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd571.65m381.16m3.26bn3.84k3.26bn3.84k
Camurus AB192.06m63.77m3.31bn280.003.31bn280.00
Humanwell Healthcare Group Co Ltd2.58bn152.20m3.34bn17.65k3.34bn17.65k
Shanghai Junshi Biosciences Co Ltd264.53m-101.20m3.38bn2.67k3.38bn2.67k
GlaxoSmithKline Pharmaceuticals Ltd303.54m78.18m3.39bn3.11k3.39bn3.11k
China Medical System Holdings Ltd836.75m175.71m3.42bn6.10k3.42bn6.10k
Amneal Pharmaceuticals Inc2.17bn4.36m3.43bn8.10k3.43bn8.10k
Hikma Pharmaceuticals Plc2.40bn274.31m3.44bn9.31k3.44bn9.31k
Beijing Tiantan Biological Products Corp684.36m140.22m3.51bn5.30k3.51bn5.30k
Data as of Feb 06 2026. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX

Institutional shareholders

28.09%Per cent of shares held by top holders
HolderShares% Held
JPMorgan (Suisse) SAas of 01 Jan 202614.01m6.31%
Boston Partners Global Investors, Inc.as of 03 Nov 202513.67m6.16%
Wellington Management Co. LLPas of 25 Feb 202511.15m5.03%
BlackRock Advisors (UK) Ltd.as of 25 Feb 20254.45m2.01%
The Vanguard Group, Inc.as of 01 Jan 20264.19m1.89%
Jupiter Asset Management Ltd.as of 31 Oct 20254.19m1.89%
Mawer Investment Management Ltd.as of 01 Jan 20263.62m1.63%
Royal London Asset Management Ltd.as of 01 Jan 20262.92m1.32%
Invesco Asset Management Ltd.as of 01 Jan 20262.18m0.98%
BlackRock Investment Management (UK) Ltd.as of 01 Jan 20261.93m0.87%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.